Journal Academy Formulary (JACF)

Journal Academy

Efbemalenograstim Alfa

Regulations: had been registered in the United States of America (Ryzneuta).

Registration number (S.A.): Not available.

Insurance Drug Formulary (S.A.): Not available.

General Information:

Registered Company: Evive Biotech.

Regulatory Status: R.X.

Mechanism of Action: colony-stimulating factor that works on hematopoietic cells by binding to specific cell surface receptors, then stimulating proliferation, commitment, differentiation, and end-cell functional activation

Indication

Approved (Labeled) indication: Neutropenia Associated with Chemotherapy

Dose: 20 mg sub Q administered once / chemotherapy cycle

Dose in Renal/Hepatic failure/Geriatric Dose: No dosage adjustment is needed

Adjustment required in Specific population: No dosage adjustment is needed.

Indicated for pediatrics: Safety and effectiveness not established in pediatric patients Safety.

Common Adverse Reactions (%): Nausea.

Severe/rare adverse Reactions (%): Aortitis and Capillary leak syndrome.

Contraindications: Allergies to granulocyte stimulating factors

Precautions: Hypotension, hypoalbuminemia, edema, hemoconcentration, Glomerulonephritis, and Leukocytosis have been reported.

Monitoring Requirements: CBC and monitor platelet counts.

Sound-Alikes/ Look-Alikes: Not available.

High Alert: Not available.

Boxed warnings or alerts issue: Not available.

Toxicity if antidote required: Not available.

Storage if there is a particular condition: Store in the original carton refrigerated between (2-8°C).

Cost Analysis

Drugs	Drug classes	Approval Indication	Dose	Cost (American Dollar)	Insurance drug formulary(SCHI)
Efbemalenograstim alfa-vuxw	Blood Modifier Agent	Neutropenia Associated with Chemotherapy	20 mg sub Q	Costs about $3,500 per dose	Not Covered

REFERENCE

1. Product Information: RYZNEUTA(R) subcutaneous injection, efbemalenograstim alfa-vuxw subcutaneous injection. Acrotech Biopharma (per manufacturer), East Windsor, NJ, 2023.

Juman Alsaab, Pharm D
Ministry of Health, Riyadh, SAUDI ARABIA.

Received: 11-05-2023;
Accepted: 10-08-2023.

Access this article online

www.ijpcs.net

DOI: 10.5530/ijpcs.2024.13.11